Total Payments
$5,732
2023 Payments
$106.73
Companies
9
Transactions
33
Medicare Patients
2,275
Medicare Billing
$222,748
Payment Breakdown by Category
Consulting$3,106 (54.2%)
Food & Beverage$1,897 (33.1%)
Travel$510.13 (8.9%)
Education$218.25 (3.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,106 | 1 | 54.2% |
| Food and Beverage | $1,897 | 26 | 33.1% |
| Travel and Lodging | $510.13 | 2 | 8.9% |
| Education | $218.25 | 4 | 3.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $4,004 | 15 | $0 (2018) |
| Celgene Corporation | $364.99 | 3 | $0 (2019) |
| Genentech USA, Inc. | $313.67 | 3 | $0 (2019) |
| Amgen Inc. | $284.34 | 3 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $239.24 | 2 | $0 (2019) |
| Lilly USA, LLC | $197.73 | 2 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $151.58 | 3 | $0 (2019) |
| AbbVie, Inc. | $98.80 | 1 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $77.55 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $106.73 | 1 | Lilly USA, LLC ($106.73) |
| 2020 | $111.94 | 1 | Amgen Inc. ($111.94) |
| 2019 | $541.25 | 6 | Celgene Corporation ($127.67) |
| 2018 | $1,024 | 10 | PFIZER INC. ($400.45) |
| 2017 | $3,948 | 15 | PFIZER INC. ($3,603) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/18/2023 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | Cash or cash equivalent | $106.73 | General |
| Category: Immunology | ||||||
| 01/16/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $111.94 | General |
| Category: Inflammation | ||||||
| 11/20/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $77.55 | General |
| 08/27/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $98.80 | General |
| Category: Immunology | ||||||
| 05/30/2019 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Education | In-kind items and services | $100.00 | General |
| Category: BioOncology/Immunology | ||||||
| 03/14/2019 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $127.67 | General |
| Category: Dermatology | ||||||
| 02/15/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.03 | General |
| 02/01/2019 | Regeneron Healthcare Solutions, Inc. | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $117.20 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/08/2018 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $91.00 | General |
| 07/09/2018 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Education | In-kind items and services | $100.00 | General |
| Category: BioOncology/Immunology | ||||||
| 06/27/2018 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $118.77 | General |
| Category: Immunology | ||||||
| 06/26/2018 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $74.40 | General |
| 05/23/2018 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $121.55 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/03/2018 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $3.63 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/10/2018 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $116.99 | General |
| Category: Dermatology | ||||||
| 02/28/2018 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $266.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 02/06/2018 | PFIZER INC. | XELJANZ (Drug) | Education | In-kind items and services | $8.47 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/20/2018 | Regeneron Healthcare Solutions, Inc. | KEVZARA SARILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $122.04 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/23/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $3.24 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/09/2017 | PFIZER INC. | XELJANZ (Drug) | Education | In-kind items and services | $9.78 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/01/2017 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $12.78 | General |
| 07/26/2017 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $113.67 | General |
| Category: Immunology | ||||||
| 07/24/2017 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $3,106.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/30/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $6.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/09/2017 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $243.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 480 | 719 | $163,749 | $51,551 |
| 2022 | 8 | 566 | 849 | $193,642 | $59,231 |
| 2021 | 7 | 570 | 855 | $170,883 | $59,373 |
| 2020 | 11 | 659 | 937 | $174,797 | $52,593 |
Total Patients
2,275
Total Services
3,360
Medicare Billing
$222,748
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 218 | 328 | $69,948 | $21,921 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 131 | 212 | $63,612 | $20,048 | 31.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $20,388 | $6,938 | 34.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 34 | 49 | $7,528 | $2,581 | 34.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 45 | 78 | $2,273 | $63.61 | 2.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 254 | 391 | $83,969 | $25,431 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 137 | 222 | $67,502 | $20,602 | 30.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $16,143 | $4,813 | 29.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $8,319 | $2,885 | 34.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 38 | 52 | $7,930 | $2,580 | 32.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 39 | $6,469 | $2,253 | 34.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 11 | 11 | $2,370 | $602.90 | 25.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 50 | 75 | $940.00 | $63.11 | 6.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 254 | 421 | $77,489 | $28,284 | 36.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 119 | 191 | $51,631 | $17,777 | 34.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 57 | 57 | $22,258 | $6,663 | 29.9% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 47 | 72 | $10,496 | $3,636 | 34.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 32 | 32 | $6,112 | $1,972 | 32.3% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 16 | 19 | $2,133 | $768.02 | 36.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 45 | 63 | $764.00 | $273.76 | 35.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 253 | 395 | $69,520 | $20,313 | 29.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 117 | 179 | $46,003 | $13,222 | 28.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 46 | 46 | $17,894 | $5,594 | 31.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 67 | 75 | $12,980 | $4,459 | 34.4% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2020 | 40 | 64 | $9,504 | $3,171 | 33.4% |
About Dr. Stuart Schwartz, MD
Dr. Stuart Schwartz, MD is a Rheumatology healthcare provider based in E. Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821038951.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Schwartz, MD has received a total of $5,732 in payments from pharmaceutical and medical device companies, with $106.73 received in 2023. These payments were reported across 33 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($3,106).
As a Medicare-enrolled provider, Schwartz has provided services to 2,275 Medicare beneficiaries, totaling 3,360 services with total Medicare billing of $222,748. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location E. Providence, RI
- Active Since 06/07/2006
- Last Updated 10/12/2016
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1821038951
Products in Payments
- XELJANZ (Drug) $3,999
- Otezla (Drug) $476.93
- Rituxan (Biological) $200.00
- KEVZARA SARILUMAB INJECTION (Biological) $122.04
- ORENCIA (Biological) $118.77
- KEVZARA (Biological) $117.20
- Actemra (Biological) $113.67
- TALTZ (Drug) $106.73
- Humira (Biological) $98.80
- LYRICA (Drug) $4.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.